Bekyree — Class III drug recall D-1055-2020
Terminated recall by Lupin Pharmaceuticals Inc., reported 2020-03-18, distributed nationwide. Failed Content Uniformity Specifications: Out Of Specification test results observed for content and blend uni
| Recall number | D-1055-2020 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2020-03-09 |
| Classified | 2020-03-24 |
| Reported by FDA | 2020-03-18 |
| Terminated | 2021-05-25 |
| Distributed | Nationwide (US) |
| Quantity | 1,712 cartons |
| Reason classes | specification failure |
| NDC | 68180-0879-11, 68180-0879-13 |
| Lot numbers | L800915 |
| Expiration dates | 2020-07-20 |
Product
Bekyree (desogestrel and ethinyl estradiol tablets USP, 0.15 mg/0.02 mg and ethinyl estradiol tablets USP, 0.01 mg), packaged in 1 Wallet of 28 Tablets (NDC 68180-879-11), 3 Wallets of 28 Tablets Each per carton (NDC 68180-879-13), Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Pithampur (M.P.) - 454775, INDIA.
Reason for recall
Failed Content Uniformity Specifications: Out Of Specification test results observed for content and blend uniformity.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1055-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.